Nibestan (Exemestane)

Exemestane, the active ingredient in Nibestan, is an aromatase inhibitor presented as an oral tablet for oral administration. It is indicated for hormone receptor‑positive breast cancer in postmenopausal women, where it lowers systemic estrogen levels and thereby helps to slow or stop the growth of estrogen‑dependent tumor cells.

GNH USA supplies Nibestan as a licensed, GDP‑compliant product to hospitals, oncology centres, pharmacies and clinics worldwide, adhering to international quality standards and regulatory requirements, including batch release testing and cold‑chain logistics where required.

Exemestane is an aromatase inhibitor used in hormone‑driven breast cancer therapy.

- Hormone receptor‑positive breast cancer (postmenopausal): Reduces estrogen‑driven tumor progression. - Early‑stage breast cancer (adjuvant setting): Decreases risk of disease recurrence after surgery. - Metastatic breast cancer: Provides systemic estrogen suppression for disease control. - Advanced breast cancer after tamoxifen failure: Offers an alternative estrogen‑lowering strategy.

Exemestane may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: Sudden feeling of warmth and sweating. - Joint and muscle pain: Discomfort in joints or muscles. - Fatigue: Persistent tiredness not relieved by rest. - Nausea: Mild to moderate upset stomach. - Headache: Pressure or throbbing pain in the head. - Decreased bone mineral density: Reduced bone strength over time.

Serious or Rare Side Effects: - Deep vein thrombosis: Blood clot formation in deep veins. - Pulmonary embolism: Blockage of lung arteries by a clot. - Severe liver injury: Elevated liver enzymes or hepatitis. - Osteoporotic fractures: Breaks due to weakened bones. - Severe allergic reaction: Rash, swelling, or breathing difficulty. - Hypercholesterolemia: Marked increase in blood cholesterol levels.

Before starting Exemestane, several safety considerations are recommended.

- Assess bone health: Monitor bone mineral density and consider calcium/vitamin D supplementation. - Evaluate liver function: Perform baseline liver enzyme tests and repeat as needed. - Avoid use in pregnancy: Category D; contraindicated in pregnant women. - Review cardiovascular risk: Consider history of thrombosis or clotting disorders. - Monitor lipid profile: Check cholesterol levels periodically. - Store at ambient temperature: Keep in original container, protect from moisture and light.

Exemestane can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Estrogen replacement therapy: Counteracts estrogen‑lowering effect. - Strong CYP3A4 inducers (e.g., rifampin): May reduce drug exposure. - Tamoxifen: Potential antagonistic hormonal effects.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., ketoconazole): May increase plasma levels. - Selective serotonin reuptake inhibitors (SSRIs): Possible effect on hormone metabolism. - Warfarin: May alter anticoagulant response; monitor INR.